Abstract
Hereditary angioedema (HAE) with C1-inhibitor (C1-Inh) deficiency (C1-Inh-HAE) is a rare, life-threatening, and disabling genetic disorder characterized by self-limited tissue swelling caused by deficiency or dysfunction of C1-Inh. Our aim in this update is to discuss new advances in HAE therapy, focusing mainly on the various treatment options that have become available recently and also drugs that are under trial for prophylaxis to prevent attacks. There is a paradigm shift to where the treatment of HAE is headed, focusing now on prophylactic treatment rather than abortive management.
Subject
General Pharmacology, Toxicology and Pharmaceutics,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference50 articles.
1. Treatment of hereditary angioedema: a review (CME).;N Bhardwaj;Transfusion.,2014
2. Hereditary angioedema: epidemiology, management, and role of icatibant.;A Ghazi;Biologics.,2013
3. Hereditary angioedema: an infrequent cause of abdominal pain with ascites.;A Talavera;Am J Gastroenterol.,1995
4. C1 inhibitor deficiency: consensus document.;M Gompels;Clin Exp Immunol.,2005
5. Hereditary angioedema: a broad review for clinicians.;U Nzeako;Arch Intern Med.,2001
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献